Stockscreener 앱 받기
76.55
1.97%
1.48
전일 마감가:
$75.07
열려 있는:
$75.93
하루 거래량:
1.07M
Relative Volume:
0.61
시가총액:
$13.86B
수익:
$342.96M
순이익/손실:
$-864.29M
주가수익비율:
-13.79
EPS:
-5.55
순현금흐름:
$-636.03M
1주 성능:
+2.22%
1개월 성능:
-3.48%
6개월 성능:
+2.53%
1년 성능:
+190.95%
1일 변동 폭
$75.70
$77.41
1주일 범위
$71.57
$77.41
52주 변동 폭
$21.92
$84.91
Insmed Inc Stock (INSM) Company Profile
명칭
Insmed Inc
전화
908-977-9900
주소
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
INSM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
76.55 | 13.86B | 342.96M | -864.29M | -636.03M | -5.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
504.77 | 129.62B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
666.87 | 72.91B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
604.96 | 36.76B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.76 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.19 | 27.86B | 3.32B | -860.46M | -1.04B | -8.32 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2024-04-23 | 개시 | Truist | Buy |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-07-26 | 개시 | Guggenheim | Buy |
| 2022-12-09 | 개시 | Mizuho | Buy |
| 2022-12-07 | 개시 | Barclays | Overweight |
| 2022-11-18 | 개시 | BofA Securities | Buy |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2021-12-06 | 개시 | JP Morgan | Overweight |
| 2021-10-19 | 재개 | Monness Crespi & Hardt | Buy |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-10-12 | 재개 | Stifel | Buy |
| 2019-09-03 | 개시 | Goldman | Buy |
| 2019-04-09 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-15 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-01-02 | 개시 | Canaccord Genuity | Buy |
| 2018-08-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | 개시 | Goldman | Neutral |
| 2018-04-23 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | 개시 | Morgan Stanley | Overweight |
| 2018-01-18 | 개시 | Credit Suisse | Neutral |
| 2017-09-05 | 재확인 | Evercore ISI | Outperform |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-07-11 | 개시 | Robert W. Baird | Outperform |
| 2016-03-15 | 개시 | Stifel | Buy |
| 2015-11-09 | 다운그레이드 | UBS | Buy → Neutral |
| 2015-10-06 | 재확인 | H.C. Wainwright | Buy |
| 2015-06-09 | 개시 | Citigroup | Neutral |
| 2014-03-26 | 재확인 | HC Wainwright | Buy |
모두보기
Insmed Inc 주식(INSM)의 최신 뉴스
Truist maintains Buy on Insmed stock, sees PAH data as positive - Investing.com Australia
US Bancorp DE Boosts Holdings in Insmed Incorporated (NASDAQ:INSM) - Defense World
Truist maintains Buy on Insmed stock, sees PAH data as positive By Investing.com - Investing.com South Africa
Insmed at Leerink Global Healthcare Conference: Optimism for Brenzo’s Launch By Investing.com - Investing.com South Africa
Insider Sell: Roger Adsett Sells 42,975 Shares of Insmed Inc (IN - GuruFocus.com
Insmed at Leerink Global Healthcare Conference: Optimism for Brenzo’s Launch - Investing.com
Insmed Incorporated (NASDAQ:INSM) Shares Acquired by Smartleaf Asset Management LLC - Defense World
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Citizentribune
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -March 10, 2025 at 08:01 am EDT - Marketscreener.com
Insmed Expands Team with Stock Options Grant to 18 New Hires - StockTitan
UBS Group Raises Insmed (NASDAQ:INSM) Price Target to $110.00 - Defense World
Insmed’s Strategic Growth and Promising Pipeline Drive Buy Rating - TipRanks
UBS raises Insmed stock price target to $110 By Investing.com - Investing.com UK
Insmed CEO Lewis sells $1.99 million in stock By Investing.com - Investing.com Australia
Insmed CEO Lewis sells $1.99 million in stock - Investing.com India
Amalgamated Bank Boosts Stake in Insmed Incorporated (NASDAQ:INSM) - Defense World
Sanctuary Advisors LLC Acquires 464 Shares of Insmed Incorporated (NASDAQ:INSM) - Defense World
Insmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024 - Star Tribune
RBC Capital starts Insmed at Outperform on brensocatib launch momentum - MSN
Guggenheim Reaffirms Buy Rating for Insmed (NASDAQ:INSM) - MarketBeat
Investor Network: Insmed Incorporated to Host Earnings Call - ACCESS Newswire
Major Public Health Interest? Scholar, Insmed & Soleno Ask EMA To Fast-Track Their Products - Pink Sheet
Truist Financial Corp Boosts Stake in Insmed Incorporated (NASDAQ:INSM) - Defense World
Insmed (NASDAQ:INSM) Now Covered by Royal Bank of Canada - MarketBeat
Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates - MSN
RBC Capital Initiates Coverage of Insmed (LSE:0JAV) with Outperform Recommendation - Nasdaq
Insmed Incorporated (NASDAQ:INSM) Given Average Recommendation of “Buy” by Brokerages - Defense World
Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says - Benzinga
RBC Capital sets $100 price target on Insmed stock with Outperform rating - Investing.com Canada
RBC Capital Initiates Coverage of Insmed (INSM) with Outperform Recommendation - MSN
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Insmed to Benefit From Strong Launch of Brensocatib for Lung Disease, RBC Says -February 25, 2025 at 12:09 pm EST - Marketscreener.com
FDA sets PDUFA date for Insmed's bronchiectasis drug By Investing.com - Investing.com Australia
FDA sets PDUFA date for Insmed’s bronchiectasis drug By Investing.com - Investing.com Nigeria
Insmed’s Brensocatib Receives FDA Priority Review - TipRanks
International Markets and Insmed (INSM): A Deep Dive for Investors - Yahoo Finance
FDA sets PDUFA date for Insmed's bronchiectasis drug - Investing.com India
FDA sets PDUFA date for Insmed’s bronchiectasis drug - Investing.com
Could This Novel Drug Transform Bronchiectasis Treatment? FDA Signals Confidence in Brensocatib - StockTitan
Insider Sell: Sara Bonstein Sells 18,322 Shares of Insmed Inc (I - GuruFocus.com
Truist Financial Increases Insmed (NASDAQ:INSM) Price Target to $108.00 - Defense World
UBS raises Insmed stock target to $105, maintains buy rating By Investing.com - Investing.com Nigeria
Insmed’s Earnings Call Highlights Record Growth and Strategic Moves - TipRanks
Insmed (NASDAQ:INSM) Shares Gap Down on Disappointing Earnings - MarketBeat
UBS Adjusts Insmed Price Target to $105 From $84, Maintains Buy Rating -February 21, 2025 at 10:46 am EST - Marketscreener.com
Insmed Inc (INSM) Q4 2024 Earnings Call Highlights: Record Reven - GuruFocus.com
UBS raises Insmed stock target to $105, maintains buy rating - Investing.com India
Decoding Insmed Inc (INSM): A Strategic SWOT Insight - GuruFocus.com
Insmed Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Insmed Inc (INSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Insmed Inc 주식 (INSM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lewis William | Chair and CEO |
Mar 03 '25 |
Option Exercise |
10.85 |
6,830 |
74,106 |
240,754 |
| Lewis William | Chair and CEO |
Mar 03 '25 |
Sale |
77.79 |
18,750 |
1,458,519 |
334,186 |
| Lewis William | Chair and CEO |
Mar 03 '25 |
Sale |
77.79 |
6,830 |
531,278 |
233,924 |
0.61%
자본화:
|
볼륨(24시간):